Modulite technology in the development of formoterol HFA pMDI: clinical evidence and future opportunities.

Expert Rev Respir Med

Hôpital Arnaud de Villeneuve 371, Avenue du Doyen Gaston Giraud, FR-34000, Montpellier, France.

Published: February 2008

This article is based on published safety and efficacy data on formoterol pressurized metered-dose inhalers (pMDIs) developed with the Modulite technology. This technology allows the development of ozone-friendly inhaled drugs that replace the same doses of chlorofluorocarbon (CFC)-formulated products and enables the attainment of new formulations with extra-fine particles and improved lung deposition. Clinical pharmacology, as well as clinical studies against comparators, have demonstrated that formoterol Modulite and the existing dry powder inhaler and CFC formoterol formulations have a similar pharmacokinetic profile, are clinically equivalent in bronchodilating effects and exhibit a similar potential for systemic side effects. Therefore, the Modulite formoterol hydrofluoroalkane-based formulation in extra-fine particles is a valuable therapeutic option for both patients and physicians in the management of asthma and chronic obstructive pulmonary disease.

Download full-text PDF

Source
http://dx.doi.org/10.1586/17476348.2.1.27DOI Listing

Publication Analysis

Top Keywords

modulite technology
8
extra-fine particles
8
formoterol
5
modulite
4
technology development
4
development formoterol
4
formoterol hfa
4
hfa pmdi
4
pmdi clinical
4
clinical evidence
4

Similar Publications

Artificial intelligence/machine learning for epilepsy and seizure diagnosis.

Epilepsy Behav

June 2024

Departments of Neurology, NYU Grossman School of Medicine, New York, NY, United States. Electronic address:

Accurate seizure and epilepsy diagnosis remains a challenging task due to the complexity and variability of manifestations, which can lead to delayed or missed diagnosis. Machine learning (ML) and artificial intelligence (AI) is a rapidly developing field, with growing interest in integrating and applying these tools to aid clinicians facing diagnostic uncertainties. ML algorithms, particularly deep neural networks, are increasingly employed in interpreting electroencephalograms (EEG), neuroimaging, wearable data, and seizure videos.

View Article and Find Full Text PDF

Background: The efficacy of inhaled corticosteroids (ICS) in moderately severe COPD patients remains unclear. At the same time, the use of extrafine particles in COPD patients is a topic of ongoing research.

Objectives: This study assessed the effect of ICS in steroid-naïve mild COPD patients and the effect of reducing the ICS dose in more severe COPD patients previously using ICS when switching to an extrafine particle BDP/F formulation (Foster using Modulite technology, Chiesi Pharmaceutici, Parma, Italy).

View Article and Find Full Text PDF

Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations.

J Asthma Allergy

February 2013

Dipartimento di Biomedicina e Medicina Interna e Specialistica, Sezione di Pneumologia, University of Palermo, Palermo, Italy.

The mainstay of management in asthma is inhalation therapy at the target site, with direct delivery of the aerosolized drug into the airways to treat inflammation and relieve obstruction. Abundant evidence is available to support the concept that inflammatory and functional changes at the level of the most peripheral airways strongly contribute to the complexity and heterogeneous manifestations of asthma. It is now largely accepted that there is a wide range of clinical phenotypes of the disease, characterized primarily by small airways involvement.

View Article and Find Full Text PDF

Asthma is a chronic inflammatory disorder of the airways that requires long-term treatment, the goal of which is to control clinical symptoms for extended periods with the least possible amount of drugs. International guidelines recommend the addition of an inhaled long-acting beta2-agonist (LABA) to a low- to medium-dose inhaled corticosteroid (ICS) when low doses of ICS fail to control asthma symptoms. The fixed combined administration of ICS/LABA improves patient compliance, reducing the risk of therapy discontinuation.

View Article and Find Full Text PDF

Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma.

Expert Rev Respir Med

April 2008

Cardio-Thoracic and Vascular Department, University of Pisa, via Paradisa 2, 56124 Pisa, Italy.

The fixed combination of beclomethasone and formoterol (BDP/F) is an extrafine hydrofluoroalkane-propelled formulation characterized by a small particle size and high particle deposition in the lower airways. The product is manufactured using a specific technology known as Modulite((R)), the advantages of which include a stable and uniform dose delivery and flexibility to tailor particle size. The high fraction of drug available for lung deposition and the resulting low fraction remaining in the upper airways account for a high efficacy coupled with a low systemic bioavailability, therefore making this combination competitive compared with other inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) fixed combinations currently available.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!